Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates
- PMID: 30481371
- PMCID: PMC7775040
- DOI: 10.1002/jso.25294
Assessment of hospital-level adjusted breast cancer sentinel lymph node positivity rates
Abstract
Background/objectives: Proficiency of performing sentinel lymph node biopsy (SLNB) for breast cancer varies among hospitals and may be reflected in the hospital's SLNB positivity rate. Our objectives were to examine whether hospital characteristics are associated with variation in SLNB positivity rates and whether hospitals with lower-than-expected SLNB positivity rates have worse patient survival.
Methods: Using the National Cancer Data Base, stage I to III breast cancer patients were identified (2004-2012). Hospital-level SLNB positivity rates were adjusted for tumor and patient factors. Hospitals were divided into terciles of SLNB positivity rates (lower-, higher-, as-expected). Hospital characteristics and survival were examined across terciles.
Results: Of 438 610 SLNB patients (from 1357 hospitals), 78 104 had one or more positive SLN (21.3%). Hospitals in the low and high terciles were more likely to be low volume (low: RRR, 4.40; 95% CI, 2.89-6.57; P < 0.001; and high: RRR, 1.79; 95% CI, 1.21-2.64; P < 0.001) compared to hospitals with as-expected (middle tercile) SLNB positivity rates. Stage I patients at low- and high-tercile hospitals had statistically worse survival.
Conclusions: There is a wide variation in hospital SLNB positivity rates. Hospitals with lower- or higher-than-expected SLNB positivity rates were associated with survival differences. Hospital SLNB positivity rates may be a novel 'process measure' to report to hospitals for internal quality assessment.
Keywords: breast cancer; health outcomes; node biopsy; process measures; quality metric; sentinel lymph.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Adjusted Hospital Sentinel Lymph Node Positivity Rates in Melanoma: A Novel Potential Measure of Quality.Ann Surg. 2016 Feb;263(2):392-8. doi: 10.1097/SLA.0000000000001052. Ann Surg. 2016. PMID: 26488806
-
The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer.Medicine (Baltimore). 2016 Aug;95(31):e4392. doi: 10.1097/MD.0000000000004392. Medicine (Baltimore). 2016. PMID: 27495053 Free PMC article.
-
Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer.Histopathology. 2017 Dec;71(6):866-873. doi: 10.1111/his.13305. Epub 2017 Sep 22. Histopathology. 2017. PMID: 28677240
-
Sentinel lymph node biopsy in breast cancer: a technical and clinical appraisal.Nucl Med Commun. 2016 Jun;37(6):570-6. doi: 10.1097/MNM.0000000000000489. Nucl Med Commun. 2016. PMID: 26886421 Review.
-
Review of Novel Sentinel Lymph Node Biopsy Techniques in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.Clin Breast Cancer. 2018 Aug;18(4):e555-e559. doi: 10.1016/j.clbc.2018.01.004. Epub 2018 Jan 31. Clin Breast Cancer. 2018. PMID: 29429940 Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
-
- Morton DL. Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am. 1997;3(6):328–330. - PubMed
-
- Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999;134(7):764–767. - PubMed
-
- Veenstra HJ, Wouters MJWM, Kroon BBR, Olmos RAV, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104(5):454–457. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical